Should I buy or sell Portage Biotech stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Portage Biotech in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PRTG shares. View PRTG analyst ratings or view top-rated stocks .

What is Portage Biotech's stock price target for 2024?

2 analysts have issued 1 year price objectives for Portage Biotech's stock. Their PRTG share price targets range from $6.00 to $11.00. On average, they expect the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 3,036.5% from the stock's current price. View analysts price targets for PRTG or view top-rated stocks among Wall Street analysts .

How have PRTG shares performed in 2024?

Portage Biotech's stock was trading at $1.82 at the beginning of the year. Since then, PRTG stock has decreased by 85.1% and is now trading at $0.2710. View the best growth stocks for 2024 here .

Are investors shorting Portage Biotech?

Portage Biotech saw a decrease in short interest in March. As of March 31st, there was short interest totaling 6,500 shares, a decrease of 57.8% from the March 15th total of 15,400 shares. Based on an average daily trading volume, of 59,500 shares, the short-interest ratio is presently 0.1 days. Approximately 0.1% of the company's shares are short sold. View Portage Biotech's Short Interest .

When is Portage Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, July 29th 2024. View our PRTG earnings forecast .

How were Portage Biotech's earnings last quarter?

Portage Biotech Inc. (NASDAQ:PRTG) announced its earnings results on Wednesday, February, 28th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.09.

How do I buy shares of Portage Biotech?

Shares of PRTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PRTG

Portage Biotech (PRTG) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free PRTG Stock Alerts

$0.27

+0.03 (+12.45%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.23
▼
$0.31
50-Day Range: $0.22
▼
$0.70
52-Week Range: $0.20
▼
$4.40

Volume: 287,861 shs
Average Volume: 79,354 shs
Market Capitalization: $4.82 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.50

Get Portage Biotech alerts:

Portage Biotech MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 3,036.5% Upside
$8.50 Price Target
Short Interest: Healthy
0.07% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.03) to ($0.65) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.29 out of 5 stars

3.3

Analyst's Opinion

Consensus Rating
Portage Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Portage Biotech has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.07% of the float of Portage Biotech has been sold short.
Short Interest Ratio / Days to Cover
Portage Biotech has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Portage Biotech has recently decreased by 57.79%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Portage Biotech does not currently pay a dividend.
Dividend Growth
Portage Biotech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PRTG.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Portage Biotech this week, compared to 0 articles on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Portage Biotech insiders have not sold or bought any company stock.
Percentage Held by Insiders
42.07% of the stock of Portage Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 13.36% of the stock of Portage Biotech is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Portage Biotech are expected to grow in the coming year, from ($1.03) to ($0.65) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Portage Biotech is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Portage Biotech is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Portage Biotech has a P/B Ratio of 0.06. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Portage Biotech Stock (NASDAQ:PRTG)

Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.

PRTG Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PRTG Stock News Headlines

April 14, 2024 | investing.com

Portage Biotech halts trial enrollment, seeks strategic options

April 12, 2024 | msn.com

Portage Down on Announcing Alternatives

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 12, 2024 | globenewswire.com

Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives

March 26, 2024 | globenewswire.com

Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

March 11, 2024 | finance.yahoo.com

PRTG: Extending the Runway

March 3, 2024 | morningstar.com

Portage Biotech Inc PRTG

February 28, 2024 | globenewswire.com

Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

January 8, 2024 | realmoney.thestreet.com

H.C. Wainwright downgrades Portage Biotech on financing overhang

January 8, 2024 | realmoney.thestreet.com

Portage Biotech just downgraded at H.C. Wainwright, here's why

January 8, 2024 | finance.yahoo.com

PRTG: Bridging I-O: Working in Harmony with Checkpoints

January 4, 2024 | marketwatch.com

Portage Biotech Shares Fall 6% on Job Reductions, Paused Drug Development Program

January 4, 2024 | markets.businessinsider.com

Portage Biotech To Pause INKT Clinical Development; To Evaluate Potential Strategic Options

January 4, 2024 | msn.com

Portage Biotech to halt iNKT drug program, cut workforce

January 4, 2024 | finance.yahoo.com

Portage Biotech Reports Business and Strategic Update

November 28, 2023 | msn.com

Portage Biotech GAAP EPS of -$0.29

November 28, 2023 | finance.yahoo.com

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update

November 6, 2023 | benzinga.com

Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

November 6, 2023 | finance.yahoo.com

Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

October 31, 2023 | msn.com

Portage Biotech files to sell 9.63M shares for holders

September 29, 2023 | finance.yahoo.com

Portage Biotech Announces $6.0 Million Registered Direct Offering

September 20, 2023 | finance.yahoo.com

Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

September 7, 2023 | markets.businessinsider.com

Analyst Expectations for Portage Biotech's Future

September 5, 2023 | marketwatch.com

Portage Biotech in Keytruda Collaboration With Merck

September 5, 2023 | finance.yahoo.com

Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors

September 1, 2023 | msn.com

Cantor Fitzgerald Reiterates Portage Biotech (PRTG) Overweight Recommendation

See More Headlines

Receive PRTG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Portage Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/19/2024
Next Earnings (Estimated): 7/29/2024
Fiscal Year End: 3/31/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Crude petroleum & natural gas
Sub-Industry: N/A
Current Symbol: NASDAQ:PRTG
CUSIP: N/A
CIK: 1095435
Web: www.portagebiotech.com
Phone: 416-929-1806
Fax: N/A
Employees: 7
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.50
High Stock Price Target: $11.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +3,441.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($8.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-104,610,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -177.66%
Return on Assets: -129.14%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 2.78
Quick Ratio: 2.78

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.45 per share
Price / Book: 0.05

Miscellaneous

Outstanding Shares: 17,800,000
Free Float: 10,312,000
Market Cap: $4.27 million
Optionable: Optionable
Beta: 0.96

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Dr. Ian B. Walters M.B.A. (Age 55)
M.D., CEO & Chairman of Board
Comp: $967.65k
Mr. Allan J. Lee Shaw CPA (Age 60)
Chief Financial Officer
Comp: $524.08k
Mr. Steven Innaimo
Vice President of Project Management & Operations
Dr. Robert A. Kramer Ph.D.
Chief Scientific Officer
Mr. Brian Wiley (Age 56)
Chief Business Officer
Comp: $220.69k
Mr. Justin Fairchild
Vice President of Development
Mr. Joseph Ciavarella
Chief Accounting Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PRTG Stock Analysis - Frequently Asked Questions

Should I buy or sell Portage Biotech stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Portage Biotech in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PRTG shares.
View PRTG analyst ratings or view top-rated stocks.
What is Portage Biotech's stock price target for 2024?: 2 analysts have issued 1 year price objectives for Portage Biotech's stock. Their PRTG share price targets range from $6.00 to $11.00. On average, they expect the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 3,036.5% from the stock's current price.
View analysts price targets for PRTG or view top-rated stocks among Wall Street analysts.
How have PRTG shares performed in 2024?: Portage Biotech's stock was trading at $1.82 at the beginning of the year. Since then, PRTG stock has decreased by 85.1% and is now trading at $0.2710.
View the best growth stocks for 2024 here.
Are investors shorting Portage Biotech?: Portage Biotech saw a decrease in short interest in March. As of March 31st, there was short interest totaling 6,500 shares, a decrease of 57.8% from the March 15th total of 15,400 shares. Based on an average daily trading volume, of 59,500 shares, the short-interest ratio is presently 0.1 days. Approximately 0.1% of the company's shares are short sold.
View Portage Biotech's Short Interest.

When is Portage Biotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, July 29th 2024.
View our PRTG earnings forecast.
How were Portage Biotech's earnings last quarter?: Portage Biotech Inc. (NASDAQ:PRTG) announced its earnings results on Wednesday, February, 28th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.09.
How do I buy shares of Portage Biotech?: Shares of PRTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRTG) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial